Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 301–400 of 1,005
Guan, Y., Xiong, H., Feng, Y., Liao, G., Tong, T., & Pang, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0209-3 · Cited by 90
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
Graff, J. N., & Chamberlain, E. D. (2014) · Core evidence · doi:10.2147/ce.s54712 · Cited by 105
Hagemann, U. B., Wickstroem, K., Wang, E., Shea, A. O., Sponheim, K., Karlsson, J., Bjerke, R. M., Ryan, O. B., & Cuthbertson, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0251 · Cited by 81
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Rathke, H. G., Giesel, F. L., Flechsig, P., Kopka, K., Mier, W., Hohenfellner, M., Haberkorn, U., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194209 · Cited by 93
“If toxicities were comparable to those in the placebo group of the ALSYMPCA trial (14), then individual dose escalations for nonresponders were considered ethically justified; this approach resulted in a short learning phase using heterogeneous dose regimens between respective dose escalation groups.”
BackgroundEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Tucci, M., Zichi, C., Buttigliero, C., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153764 · Cited by 93
“Radium-223, an alpha-emitting bone target agent, demonstrated a prolongation of OS compared to placebo, regardless of previous treatment with docetaxel, and it was approved for symptomatic bone mCRPC patients.(10) The Food and Drug Administration (FDA) also approved sipuleucel-T, an autologous cellular immunotherapy,…”
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Pang, L., Chen, G., Xu, J. Y., Jia, Y., Chai, J., Huang, R., Li, A., Ge, H., Yu, S., & Cheng, H. (2022) · Cancers · doi:10.3390/cancers14235727 · Cited by 100
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
Hatano, K., & Nonomura, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220200 · Cited by 87
Targeting DNA Damage Response in Prostate and Breast Cancer
Wengner, A. M., Scholz, A., & Haendler, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218273 · Cited by 88
“Radium-223 was the first alpha emitter approved for CRPC patients with bone metastases and no evidence of visceral metastases, based on a significant prolongation of overall survival [184].”
BackgroundParikh, M., Liu, C., Wu, C., Evans, C. P., Dall’Era, M., Robles, D., Lara, P. N., Agarwal, N., Gao, A. C., & Pan, C.-X. (2021) · Scientific Reports · doi:10.1038/s41598-021-85969-x · Cited by 86
Faugeroux, V., Pailler, E., Oulhen, M., Déas, O., Brullé, L., Hervieu, C., Marty, V., Alexandrova, K., Andree, K., Stoecklein, N. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15426-2 · Cited by 89
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
Castration-resistant prostate cancer: latest evidence and therapeutic implications
Suzman, D. L., & Antonarakis, E. S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014529176 · Cited by 89
Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00573 · Cited by 78
Radioimmunotherapy with α-Particle-Emitting Radionuclides
Seidl, C. (2014) · Immunotherapy · doi:10.2217/imt.14.16 · Cited by 93
Shiota, M., & Eto, M. (2016) · International Journal of Urology · doi:10.1111/iju.13091 · Cited by 80
Predictors of Time to Metastasis in Castration-resistant Prostate Cancer
Moreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., Hanyok, B. T., Aronson, W. J., Kane, C. J., Terris, M. K., et al. (2016) · Urology · doi:10.1016/j.urology.2016.06.011 · Cited by 79
Heinrich, D. A., Bruland, Ø. S., Guise, T. A., Suzuki, H., & Sartor, O. A. (2018) · Future Oncology · doi:10.2217/fon-2018-0087 · Cited by 86
Self-citationParker, C. C., Finkelstein, S. E., Michalski, J. M., O’Sullivan, J. M., Bruland, Ø. S., Vogelzang, N. J., Coleman, R. E., Nilsson, S. F., Sartor, O. A., Li, R., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.002 · Cited by 77
Self-citationEnzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 85
Higano, C. S., Armstrong, A. J., Sartor, O. A., Vogelzang, N. J., Kantoff, P. W., McLeod, D. G., Pieczonka, C. M., Penson, D. F., Shore, N. D., Vacirca, J. L., et al. (2019) · Cancer · doi:10.1002/cncr.32445 · Cited by 80
“Furthermore, PROCEED spanned a period of unprecedented progress in mCRPC management as 4 life-extending therapies became available: abiraterone acetate,(17,18) enzalutamide,(19,20) cabazitaxel,(21) and radium 223.(22) Thus, in PROCEED, the median OS (30.”
BackgroundSelf-citationHERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential
He, S., Moutaoufik, M. T., Islam, S., Persad, A. R. L., Wu, A., Aly, K. A., Fonge, H., Babu, M., & Cayabyab, F. S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188355 · Cited by 80
Yang, H., Zhang, C., Yuan, Z., Rodríguez‐Rodríguez, C., Robertson, A. K. H., Radchenko, V., Perron, R., Gendron, D., Causey, P. W., Gao, F., et al. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002999 · Cited by 86
Brown, J. E., Handforth, C., Compston, J. E., Cross, W. R., Parr, N. J., Selby, P. L., Wood, S. L., Drudge‐Coates, L., Walsh, J., Mitchell, C. A., et al. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100311 · Cited by 88
“6 months [32] and a reduced risk of symptomatic skeletal related events (SSREs) [33].”
BackgroundSelf-citationImmune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 87
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
Lowrance, W. T., Roth, B. J., Kirkby, E., Murad, M. H., & Cookson, M. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.10.086 · Cited by 79
Singal, R., Ramachandran, K. J., Gordián, E. R., Quintero, C., Zhao, W. K., & dos Reis, I. M. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.07.008 · Cited by 83
Huisman, M., ter Haar, G., Napoli, A., Hananel, A., Ghanouni, P., Lövey, G., Nijenhuis, R. J., van den Bosch, M. A. A. J., Rieke, V., Majumdar, S., et al. (2015) · International Journal of Hyperthermia · doi:10.3109/02656736.2014.995237 · Cited by 77
Loriot, Y., Eymard, J., Patrikidou, A., Ileana, E. E., Massard, C., Albiges, L. K., Palma, M. D., Escudier, B. J., & Fizazi, K. S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.128 · Cited by 84
Sólnes, L. B., Werner, R. A., Jones, K. M., Sadaghiani, M. S., Bailey, C. R., Lapa, C., Pomper, M. G., & Rowe, S. P. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220665 · Cited by 81
“After multiple phase II studies (44–46), a phase III randomized, double-blind, placebo-controlled study of 921 patients with metastatic castration-resistant prostate cancer (mCRPC) with isolated osseous metastases provided the primary evidence on which is based clinical treatment of patients with 223Ra (47).”
BackgroundInfluentialLi, S., Kang, Y., & Zeng, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189033 · Cited by 83
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2978 · Cited by 76
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Sartor, O. A., Vogelzang, N. J., Sweeney, C. J., Fernandez, D. C., Almeida, F., Iagaru, A. H., Brown, A. S., Smith, M. R., Agrawal, M., Dicker, A. P., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0413 · Cited by 78
“Patients Eligibility criteria were similar to those of ALSYMPCA [6].”
BackgroundResultInfluentialSelf-citationTargeted and Nontargeted α-Particle Therapies
McDevitt, M. R., Sgouros, G., & Sofou, S. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-120931 · Cited by 81
“In contrast to this early experience, clinical trial investigations of α-particle emitters for cancer therapy show excellent potential as safe and highly effective cancer therapies in patients with few to no remaining therapeutic options (5, 6).”
MethodResultDosimetry in radionuclide therapy: the clinical role of measuring radiation dose
Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 83
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 83
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Henriquez, I., Roach, M., Morgan, T. M., Bossi, A., Gómez, J., Abuchaibe, O., & Couñago, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091247 · Cited by 85
“In 2013, the results of the pivotal phase III ALSYMPCA trial comparing Radium-223 to placebo in patients with mCRPC (n = 921) with symptomatic bone involvement but no evidence of visceral involvement was reported [20].”
BackgroundTransforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
Mirzaei, S., Paskeh, M. D. A., Saghari, Y., Zarrabi, A., Hamblin, M. R., Entezari, M., Hashemi, M., Aref, A. R., Hushmandi, K., Kumar, A. P., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.02.094 · Cited by 85
McDougall, J. A., Bansal, A., Goulart, B. H. L., McCune, J. S., Karnopp, A., Fedorenko, C. R., Greenlee, S., Valderrama, A., Sullivan, S. D., & Ramsey, S. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0327 · Cited by 73
Francini, E., Gray, K. P., Shaw, G. K., Evan, C. P., Hamid, A. A., Perry, C. E., Kantoff, P. W., Taplin, M.-E., & Sweeney, C. J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0121-2 · Cited by 74
The Future of Nuclear Medicine as an Independent Specialty
Czernin, J. G., Sonni, I., Razmaria, A. A., & Calais, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220558 · Cited by 78
“Both have largely been replaced by 223Ra treatment, which results in symptomatic relief and prolongs the survival of prostate cancer patients (42).”
BackgroundPSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
Ramnaraign, B. H., & Sartor, O. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyac279 · Cited by 76
Self-citationComputed Cerenkov luminescence yields for radionuclides used in biology and medicine
Gill, R. K., Mitchell, G. S., & Cherry, S. R. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/11/4263 · Cited by 77
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Fizazi, K. S., Albiges, L. K., Loriot, Y., & Massard, C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1081566 · Cited by 79
Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors
Wissing, M. D. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0266-z · Cited by 79
Xu, X. S., Ryan, C. J., Stuyckens, K., Smith, M. R., Saad, F., Griffin, T. W., Park, Y. C., Yu, M. K., Vermeulen, A., Poggesi, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1549 · Cited by 71
Radionuclide Therapy of Metastatic Prostate Cancer
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.003 · Cited by 71
Rozet, F., Mongiat-Artus, P., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mathiéu, R., Ploussard, G., Renard‐Penna, R., et al. (2020) · The French Journal of Urology · doi:10.1016/s1166-7087(20)30752-1 · Cited by 87
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Roudsari, N. M., Lashgari, N., Momtaz, S., Abaft, S., Jamali, F., Safaiepour, P., Narimisa, K., Jackson, G., Bishayee, A., Rezaei, N., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081195 · Cited by 75
“targeted for bone metastasis but further research demonstrated that patients with CRPC had increased survival after Radium-223 therapy [35].”
BackgroundYu, E. Y., Piulats, J. M., Gravis, G., Fong, P. C. C., Todenhöfer, T., Laguerre, B., Arranz, J. Á., Oudard, S. M., Massard, C., Heinzelbecker, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.005 · Cited by 78
Yadav, M. P., Ballal, S., Martin, M., Roesch, F., Satapathy, S., Moon, E. S., Tripathi, M., Gogia, A., & Bal, C. S. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06482-z · Cited by 79
“The α-emitter radium-223 has demonstrated a favorable impact on survival, yet its high cost and limited availability have overshadowed its potential advantages [44].”
An efficient chelator for complexation of thorium-227
Ramdahl, T., Bonge‐Hansen, H. T., Ryan, O. B., Larsen, Å., Herstad, G., Sandberg, M., Bjerke, R. M., Grant, D., Brevik, E. M., & Cuthbertson, A. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.034 · Cited by 71
The role of ketoconazole in current prostate cancer care
Patel, V. G., Liaw, B. C.-H., & Oh, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0077-y · Cited by 79
Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy406 · Cited by 71
Immunotherapy for prostate cancer: recent developments and future challenges
Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 79
Nussbaum, N., George, D. J., Abernethy, A. P., Dolan, C. M., Oestreicher, N., Flanders, S., & Dorff, T. B. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.42 · Cited by 71
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
Bastos, D. A., & Antonarakis, E. S. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1427068 · Cited by 73
“Radiopharmaceuticals ● Radium-223 ● First radiopharmaceutical to demonstrate OS benefit [10].”
BackgroundChemotherapy following radium‐223 dichloride treatment in ALSYMPCA
Sartor, O. A., Hoskin, P., Coleman, R. E., Nilsson, S. F., Vogelzang, N. J., Petrenciuc, O., Staudacher, K., Thuresson, M., & Parker, C. C. (2016) · The Prostate · doi:10.1002/pros.23180 · Cited by 71
Self-citationCurrent approaches to incorporation of radium-223 in clinical practice
Parker, C. C., Heidenreich, A., Nilsson, S. F., & Shore, N. D. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0020-y · Cited by 76
“Radium-223+ best standard of care [18] Placebo+ best standard of care 3.”
BackgroundInfluentialSelf-citationAACR Cancer Progress Report 2013
Sawyers, C. L., Abate-Shen, C. T., Anderson, K. C., Barker, A. D., Baselga, J. M., Berger, N. A., Foti, M., Jemal, A., Lawrence, T. S., Li, C. I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2107 · Cited by 81
Imaging for Metastasis in Prostate Cancer: A Review of the Literature
Turpin, A., Girard, E., Baillet, C., Pasquier, D., Olivier, J., Villers, A. A., Puech, P., & Penel, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00055 · Cited by 75
Myeloma Bone Disease: A Comprehensive Review
Mukkamalla, S. K. R., & Malipeddi, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126208 · Cited by 81
“This has been studied well in the management of metastatic prostate cancers with bone disease, using radium-223 and samarium-153 [197,198].”
BackgroundAlpha-Emitting Radionuclides: Current Status and Future Perspectives
Miederer, M., Benešová, M., Mamat, C., Kästner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., Scheinberg, D. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17010076 · Cited by 91
“The approved activity is 55 kBq/kg, administered for six cycles every 4 weeks [76].”
Ahmadzadehfar, H., Zimbelmann, S., Yordanova, A., Fimmers, R., Kürpig, S., Eppard, E., Gaertner, F. C., Wei, X. X., Hauser, S., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15698 · Cited by 75
“Currently there are different approved drugs for castrate-resistant mPC patients, all with a positive effect on overall survival (abiraterone, enzalutamide, docetaxel, cabazitaxel, and 223Ra) [12-17].”
BackgroundCarneiro, A., Wroclawski, M. L., Nahar, B., Soares, A., Cardoso, A. P. G., Kim, N. J., & de Carvalho, F. R. T. (2020) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.04.03 · Cited by 66
“Alternatively, in patients with isolated bone metastases, the use of radium 223 ADT may be considered (27).”
BackgroundMassari, F., Ciccarese, C., Caliò, A., Munari, E., Cima, L., Porcaro, A. B., Novella, G., Artibani, W., Sava, T., Eccher, A., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0396-3 · Cited by 72
Vignani, F., Bertaglia, V., Buttigliero, C., Tucci, M., Scagliotti, G. V., & Maïo, M. D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.002 · Cited by 73
Groener, D., Nguyen, C. T., Baumgarten, J., Bockisch, B., Davis, K., Happel, C., Mader, N., Ngoc, C. N., Wichert, J., Banek, S., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00805-7 · Cited by 77
Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review
Almeeri, M. N. E., Awies, M., & Constantinou, C. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01614-6 · Cited by 85
“…proven to prolong OS by almost 3 months, as shown when radium-233 was tested against a placebo in 921 patients, where the survival benefit was (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P < 0.001), and it also delayed the first symptomatic skeletal events [38].”
InfluentialImmune checkpoint inhibitors and prostate cancer: a new frontier?
Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., Tortora, G., & Massari, F. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.293 · Cited by 75
A comprehensive review of immunotherapies in prostate cancer
Maia, M. C., & Hansen, A. R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.026 · Cited by 71
Watanabe, M., Kanao, K., Suzuki, S., Muramatsu, H., Morinaga, S., Kajikawa, K., Kobayashi, I., Nishikawa, G., Kato, Y., Zennami, K., et al. (2019) · The Prostate · doi:10.1002/pros.23890 · Cited by 73
Advances in targeted alpha therapy for prostate cancer
VINCENTIS, G. D., Gerritsen, W. R., Gschwend, J. E., Hacker, M., Lewington, V. J., O’Sullivan, J. M., Oya, M., Pacilio, M., Parker, C. C., Shore, N. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz270 · Cited by 72
“Despite these results, median times to increase in prostatespecific antigen (PSA) levels were similar among treatment arms [7].”
BackgroundInfluentialSelf-citationKyriakopoulos, C. E., Eickhoff, J. C., Ferrari, A. C., Schweizer, M. T., Wargowski, E., Olson, B. M., & McNeel, D. G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0945 · Cited by 68
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
Mollica, V., Rizzo, A., Rosellini, M., Marchetti, A., Ricci, A. D., Cimadamore, A., Scarpelli, M., Bonucci, C., Andrini, E., Errani, C., et al. (2021) · Cancers · doi:10.3390/cancers13030546 · Cited by 72
“[58] mCRPC (921) Radium-223 (6 injections at a dose of 50 kBq/Kg IV Q4 W) vs.”
BackgroundInfluentialAR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
Sobhani, N., Neeli, P. K., D’Angelo, A., Pittacolo, M., Sirico, M., Galli, I. C., Roviello, G., & Nesi, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115515 · Cited by 74
“Data from the Phase III ALSYMPCA trial show that radium-dichloride (radium-223), an alpha emitter selectively targeting bone metastases with alpha particles [12], increases OS of CRPC patients in addition to the best standard of care [13].”
MethodPTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
Choudhury, A. D. (2022) · The Prostate · doi:10.1002/pros.24372 · Cited by 83
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 88
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodríguez‐Vida, A., Chowdhury, S., Sternberg, C. N., Rudman, S. M., & Galazi, M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s69433 · Cited by 77
Mukherji, D., Omlin, A. G., Pezaro, C. J., Shamseddine, A. I., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9473-1 · Cited by 67
Imaging and dosimetry for radium-223: the potential for personalized treatment
Flux, G. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160748 · Cited by 68
“6 months, with minimal toxicity.(9) Unfortunately, as no dosimetry was performed for these patients, there is as yet no evidence for correlations of absorbed dose with outcome.”
BackgroundMarshall, C. H., Fu, W., Wang, H., Park, J. C., DeWeese, T. L., Tran, P. T., Song, D. Y., King, S., Afful, M., Hurrelbrink, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4476 · Cited by 66
“This clinical signal is encouraging, as PSA responses are only seen in approximately 10%– 15% of patients treated with radium-223 and approximately 2% of patients treated with sipuleucel-T, although this could be within what is expected from radium-223 alone (1, 10, 16, 17).”
BackgroundSelf-citationVardaki, I., Corn, P. G., Gentile, E., Song, J. H., Madan, N., Hoang, A. G., Parikh, N. U., Guerra, L., Lee, Y., Lin, S.-C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4790 · Cited by 71
“Radium-223 (Ra-223) was the first bone-homing radiopharmaceutical to improve median overall survival (OS) when compared with placebo in the ALSYMPCA phase III clinical trial (10).”
BackgroundCancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 69
Molecular Targeted α-Particle Therapy for Oncologic Applications
Wadas, T. J., Pandya, D. N., Solingapuram Sai, K. K., & Mintz, A. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.14.12554 · Cited by 65
Jong, J. M. V. D.-D., Oprea‐Lager, D. E., Hooft, L., de Klerk, J. M. H., Bloemendal, H. J., Verheul, H. M. W., Hoekstra, O. S., & van den Eertwegh, A. J. M. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.005 · Cited by 65
Man, Y.-N., & Chen, Y. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02265-4 · Cited by 68
Aly, M., Levál, A., Schain, F., Liwing, J., Lawson, J., Vágó, E., Nordström, T., Andersson, T., Sjöland, E., Wang, C., et al. (2020) · Scandinavian Journal of Urology · doi:10.1080/21681805.2020.1739139 · Cited by 69
“After treatment with docetaxel plus prednisone was shown to be effective for patients with metastatic CRPC (mCRPC) [4], other therapies with positive results in clinical trials were introduced for treatment of mCRPC; these therapies included abiraterone acetate plus prednisone [5–7], cabazitaxel [8], enzalutamide [9,1…”
BackgroundBauckneht, M., Rebuzzi, S. E., Signori, A., Frantellizzi, V., Murianni, V., Rizzini, E. L., Mascia, M., Lavelli, V., Donegani, M. I., Ponzano, M., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05550-6 · Cited by 64
“Moreover, while the ALSYMPCA trial exclusively included patients with painful bone metastases [4], more recent data showed that OS tended to be longer in patients with little or no bone pain than those with moderate or severe pain [31].”
InfluentialH 2 BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy
Kadassery, K. J., King, A., Fayn, S., Baidoo, K. E., MacMillan, S. N., Escorcia, F. E., & Wilson, J. J. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00190 · Cited by 64
Recent advances and future perspectives in the therapeutics of prostate cancer
Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 80
Fichou, N., Gouard, S., Maurel, C., Barbet, J., Ferrer, L., Morgenstern, A., Bruchertseifer, F., Faivre-Chauvet, A., Bigot-Corbel, E., Davodeau, F., et al. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00076 · Cited by 64
Umeda, T., Koizumi, M., Fukai, S., Miyaji, N., Motegi, K., Nakazawa, S., & Takiguchi, T. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1224-x · Cited by 64
“We then applied this technique to metastatic prostate cancer patients receiving radium (Ra)223 therapy [17], and compared the utility of this technique with BSI.”
MethodCazzato, R. L., Koch, G., Buy, X., Ramamurthy, N. K., Tsoumakidou, G., Caudrelier, J. M., Catena, V., Garnon, J., Palussière, J., & Gangi, A. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-016-1389-z · Cited by 63
Lighting up the tumor fire with low-dose irradiation
Herrera, F. G., Romero, P. J., & Coukos, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.006 · Cited by 71
Lawal, I. O., Morgenstern, A., Vorster, M., Knoesen, O., Mahapane, J., Hlongwa, K., Maserumule, L. C., Ndlovu, H., Reed, J., Popoola, G. O., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05778-w · Cited by 66
“In addition to drug therapies such as chemotherapy with docetaxel and cabazitaxel and next-generation anti-androgen therapy with abiraterone and enzalutamide with activity against soft tissue and skeletal metastases of metastatic castration-resistant prostate cancer (mCRPC) [5–8], radium dichloride has also been shown…”
Virgo, K. S., Basch, E., Loblaw, D. A., Oliver, T. K., Rumble, R. B., Carducci, M. A., Nordquist, L. T., Taplin, M., Winquist, E., & Singer, E. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8030 · Cited by 68
Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.022 · Cited by 63
“Another taxane, cabazitaxel [9], two oral androgen-receptor axis targeted inhibitors, abiraterone acetate [10,11] and enzalutamide [12,13], an autologous therapeutic cancer vaccine, Sipuleucel-T [14], and a bone-targeted radio-pharmaceutical, radium-223 [15], have since shown improvement in overall survival in mCRPC p…”
BackgroundNew agents for prostate cancer
Agarwal, N., Lorenzo, G. D., Sonpavde, G., & Bellmunt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu038 · Cited by 71
Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT
Noto, B., Vrachimis, A., Schäfers, M. A., Stegger, L., & Rahbar, K. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001291 · Cited by 62
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.